Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans

被引:142
作者
Duan, XZ
Wang, M
Li, HW
Zhuang, H
Xu, DP
Wang, FS
机构
[1] Beijing 302 Hosp, Beijing Inst Infect Dis, Res Ctr Biol Therapy, Beijing 100039, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing 100083, Peoples R China
基金
中国国家自然科学基金;
关键词
chronic hepatitis; dendritic cells; liver cirrhosis; nosocomial infections;
D O I
10.1007/s10875-004-6249-y
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Type 2 precusor plasmacytoid dendritic cells (pDC) represent the most important cell type in antiviral innate immunity. To understand the function of pDC during hepatitis B virus infection, the frequency and function of circulating pDC were analyzed by flow cytometric analysis, and IFN-alpha secretion of total PBMCs was determined by ELISA assay in 25 healthy subjects and 116 patients at various stages of chronic hepatitis B virus infection (CHB). The number of circulating pDC was found to be significantly lower in patients with CHB and associated liver cirrhosis (LC). The ability of PBMCs to secrete IFN-alpha also decreased significantly. There was a corresponding decrease of circulating NK cells and CD8(+) T cells. We observed that lamuvidine antiviral therapy restored the number of circulating pDC and there was a reversal of pDC frequency with the control of HBV replication in chronic HBV patients, indicating these subjects are unlikely to be totally immunecompromised. The decrease of pDC was found to be related to nosocomial infections in LC patients. Our results suggest that CHB patients probably have a quantitative and qualitative impairment of circulating pDC or NK cells, which may be associated with HBV persistent infection as well as the nosocomial infections that arise in LC patients.
引用
收藏
页码:637 / 646
页数:10
相关论文
共 46 条
[1]  
Arima S, 2003, INT J MOL MED, V11, P169
[2]   Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection [J].
Auffermann-Gratzinger, S ;
Keeffe, EB ;
Levy, S .
BLOOD, 2001, 97 (10) :3171-3176
[3]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[4]   SELECTIVE KILLING OF HEPATITIS-B ENVELOPE ANTIGEN-SPECIFIC B-CELLS BY CLASS-I-RESTRICTED, EXOGENOUS ANTIGEN-SPECIFIC LYMPHOCYTES-T [J].
BARNABA, V ;
FRANCO, A ;
ALBERTI, A ;
BENVENUTO, R ;
BALSANO, F .
NATURE, 1990, 345 (6272) :258-260
[5]   Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type I response in vitro:: mechanisms for viral immune escape [J].
Beckebaum, S ;
Cicinnati, VR ;
Zhang, X ;
Ferencik, S ;
Frilling, A ;
Grosse-Wilde, H ;
Broelsch, CE ;
Gerken, G .
IMMUNOLOGY, 2003, 109 (04) :487-495
[6]   Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection [J].
Beckebaum, S ;
Cicinnati, VR ;
Dworacki, G ;
Müller-Berghaus, J ;
Stolz, D ;
Harnaha, J ;
Whiteside, TL ;
Thomson, AW ;
Lu, L ;
Fung, JJ ;
Bonham, CA .
CLINICAL IMMUNOLOGY, 2002, 104 (02) :138-150
[7]   Kinetics of the immune response during HBV and HCV infection [J].
Bertoletti, A ;
Ferrari, C .
HEPATOLOGY, 2003, 38 (01) :4-13
[8]   Activation and function of natural killer cell responses during viral infections [J].
Biron, CA .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (01) :24-34
[9]   Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy [J].
Boni, C ;
Penna, A ;
Ogg, GS ;
Bertoletti, A ;
Pilli, M ;
Cavallo, C ;
Cavalli, A ;
Urbani, S ;
Boehme, R ;
Panebianco, R ;
Fiaccadori, F ;
Ferrari, C .
HEPATOLOGY, 2001, 33 (04) :963-971
[10]   Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B [J].
Boni, C ;
Bertoletti, A ;
Penna, A ;
Cavalli, A ;
Pilli, M ;
Urbani, S ;
Scognamiglio, P ;
Boehme, R ;
Panebianco, R ;
Fiaccadori, F ;
Ferrari, C .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (05) :968-975